CVS caremark™ {{PANUMCODE}}

Rydapt

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: {{MEMFIRST}} {{MEMLAST}} **Date**: {{TODAY}}
Patient's ID {{MEMBERID}} **Patient's Date of Birth:** {{MEMBERDOB}}
Physician's Name: {{PHYFIRST}} {{PHYLAST}}
Specialty: _____, NPI#: _____
Physician Office Telephone: {{PHYSICIANPHONE}} **Physician Office Fax:** {{PHYSICIANFAX}}
Request Initiated For: {{DRUGNAME}}

1. What is the patient's diagnosis?
   - ❑ Acute myeloid leukemia (AML)
   - ❑ Aggressive systemic mastocytosis (ASM)
   - ❑ Mast cell leukemia (MCL)
   - ❑ Myeloid/lymphoid neoplasms with eosinophilia
   - ❑ Systemic mastocytosis with associated hematological neoplasm (SM-AHN)
   - ❑ Other _____
2. What is the ICD-10 code? _____
3. Is the patient currently receiving treatment with the requested medication?
   ❑ Yes ❑ No *If No, skip to diagnosis section.*
4. Is there evidence of unacceptable toxicity while on the current regimen? ❑ Yes ❑ No

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Acute Myeloid Leukemia

5. What is the patient's FLT3 mutation status? ***ACTION REQUIRED: Attach chart note(s) or test results of FLT3 mutation test result***. ❑ Positive ❑ Negative ❑ Unknown
6. Will the requested medication be used as a single-agent for induction therapy? ❑ Yes ❑ No

Section B: Myeloid/Lymphoid Neoplasms with Eosinophilia

7. Does the disease have a FGFR1 or FLT3 rearrangement? ***ACTION REQUIRED: If Yes, attach chart note(s) or test results confirming FGFR1 or FLT3 rearrangement.*** ❑ Yes ❑ No ❑ Unknown
8. Is the disease in chronic or blast phase?
   - ❑ Yes - Chronic phase
   - ❑ Yes - Blast phase
   - ❑ No

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Section C: Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN), Mast Cell Leukemia (MCL)

9. Will the requested medication be used as a single-agent? ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155